Some Common Post-Merger Compliance Issues
This article was originally published in The Gold Sheet
Executive SummaryMerging drug makers sometimes try to make do with minimal staffing of quality and compliance units – with unfortunate results, FDA’s Edwin Rivera-Martinez told the PDA/FDA conference in Washington last month.
You may also be interested in...
New approach could eliminate minor differences among authorities, enabling pharmaceutical manufacturing processes to become truly global.
The US FDA applied laboratory data integrity inspection technique to production floor, leading to warning letter, import alert.
US National Academies panel diverges on how to focus pharmaceutical inspectorates’ mutual reliance arrangements on public health goals.